Current Report Filing (8-k)
May 03 2019 - 4:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 29, 2019
DECIPHERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38219
|
|
30-1003521
|
(State or other jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
|
|
500 Totten Pond Road
Waltham, MA
|
|
02451
|
(Address of registrants principal executive office)
|
|
(Zip code)
|
(781) 209-6400
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2
of the Securities Exchange Act of 1934.
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☑
Securities registered pursuant to
Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol
|
|
Name of exchange on which
registered
|
Common Stock, $0.01 Par Value
|
|
DCPH
|
|
The Nasdaq Global Select Market
|
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
On April 29, 2019, Deciphera Pharmaceuticals, Inc., as tenant (the Company), and 200 Smith NWALP Property Owner LLC, as
landlord (the Landlord), entered into a Third Amendment to Lease (the Amendment) to the Lease between the Company and the Landlord dated May 29, 2018, as amended (the Lease), to add an additional 38,003
square feet of space (the Expansion Premises) to their existing premises of 44,343 square feet of space (the Initial Premises), for a total of 82,346 square feet of space in that building commonly known and numbered as 200
Smith Street in Waltham, Massachusetts (the Premises). The Premises will become the Companys new headquarters location.
The term of the lease for the Expansion Premises commences upon the Landlords substantial completion of the initial buildout of the
Expansion Premises, which is expected to occur on or about January 1, 2020 (the Expansion Premises Commencement Date) and shall continue for the remainder of the Lease Term, which is anticipated to expire November 30,
2029. The Company has the option to extend the Lease Term for two (2) additional periods of five (5) years each, subject to the terms and conditions of the Lease.
The initial fixed rental rate is $49.00 per rentable square foot of the Expansion Premises per annum, and will increase at a rate of $1.00 per
annum, with base rent becoming due seven (7) months following the Expansion Premises Commencement Date. Under the terms of the Amendment, the Landlord will provide an allowance in an amount not to exceed $2,280,180.00 (calculated at a rate
of $60.00 per rentable square foot of the Expansion Premises) toward the cost of completing the initial buildout of the Expansion Premises. The Company will be required pay its share of operating expenses, taxes and any other expenses payable under
the Amendment.
The Amendment is filed as Exhibit 10.1 to this Current Report on Form
8-K,
and the
above description of the Amendment is qualified in its entirety by reference to such exhibit.
Item 2.03.
|
Creation of a Direct Financial Obligation or an Obligation under an
Off-Balance
Sheet Arrangement of a Registrant.
|
The information set forth
above in Item 1.01 of this Current Report on Form
8-K
regarding the Amendment is incorporated into this Item 2.03 by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
10.1
|
|
Third Amendment to Lease, dated April 29, 2019, by and between Deciphera Pharmaceuticals, Inc. and 200 Smith NWALP Property Owner LLC.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: May 3, 2019
|
|
|
|
DECIPHERA PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Steven L. Hoerter
|
|
|
|
|
|
|
Steven L. Hoerter
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Apr 2023 to Apr 2024